Sensyne Health PLC (LON:SENS) on Friday confirmed its MagnifEye software that uses artificial intelligence to automate the accurate reading and analysis of lateral flow diagnostics has been given the green light by the UK regulator.
Specifically, the Medicines & Healthcare Products Regulatory Agency has granted Authorisation of Special Use alongside the Innova COVID-19 self-test kit.
The company said it is also pursuing sign-off for its technology for deployment with other manufacturers’ equipment and other medical indications.
Chief executive Lord Drayson said: “MagnifEye has demonstrated that it has the potential to play an important role in COVID-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation.
“We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”